louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06454565: Effects of Traditional Martial Arts, Open and Locked Exercise on the Physical and Mental Health of Drug Users
Official title: Effects of Traditional Martial Arts, Open and Locked Exercise on the Physical and Mental Health of Drug Users
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Drug Use
Lead sponsor: Northeast Normal University
Sponsor class: OTHER
First posted: 2024-06-12
Enrollment: 189
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to discuss the efficacy of Chinese traditional martial arts in reducing drug addiction and improving the physical and mental health of drug addicts.


Eligibility criteria: Inclusion Criteria:

* Normal mental state, able to understand and accept instructions
* Drug users who have survived the detoxification period
* Without major diseases

Exclusion Criteria:

* Drug use for more than 2 years
* Drug abusers who have entered a drug rehabilitation center more than once

Primary outcomes:
measure: Using a Jamar hydraulic hand dynamometer to investigate change of handgrip in participants.
timeFrame: Month 6
measure: Using a step test to test participants' aerobic endurance.
timeFrame: Month 6
measure: Using a spirometry tester to investigate changes in pulmonary capacity of the participants.
timeFrame: Month 6
measure: The participants' flexibility was tested by seated forward bending.
timeFrame: Month 6
measure: The participants reaction abilities were tested by means of a reaction time tester.
timeFrame: Month 6
measure: The balance ability of the participants was tested through a one-legged standing test.
timeFrame: Month 6
measure: The core strength of the participants was tested through a sit-up test.
timeFrame: Month 6
Secondary outcomes:
Other outcomes:
Locations:
city: Changchun
country: China
facility: Chinese Center of Exercise Epidemiology
state: Jilin
Study officials:
References:
Clinical trial NCT06416865: Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Official title: A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Essential Hypertension
Lead sponsor: AJU Pharm Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-05-16
Enrollment: 190
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament


Eligibility criteria: Inclusion Criteria:

* Adults aged ≤19 years.
* Those who voluntarily signed the informed consent to participate in this study.
* A patient diagnosed with essential hypertension or Patients taking hypertension medication
* Those who are eligible for adequate blood pressure criteria during screening tests: Naïve patient-160 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg/Patients taking hypertension medication-140 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg

Exclusion Criteria:

* At the screening visit (Visit 1), patients had 3 blood pressure measurements in the arm with the higher average MSSBP, those whose maximum and minimum blood pressure differences are MSSBP 20 mmHg and MSDBP 10 mmHg
* Secondary hypertension patients or those with a history of suspected secondary hypertension
* Cardiovascular/cerebrovascular disease
* Those with a history of malignant tumor within 5 years

Primary outcomes:
measure: Changes in MSSBP(mean sitting systolic blood pressure)
timeFrame: 8th week
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: AJU Pharm Co., Ltd.
Study officials:
References:
Clinical trial NCT06871865: The Effects of Oculomotor Training on Pain, Cervical Range of Motion, Joint Position Sense, Endurance, and Balance in Individuals with Mechanical Neck Pain
Official title: The Effects of Oculomotor Training on Pain, Cervical Range of Motion, Joint Position Sense, Endurance, and Balance in Individuals with Mechanical Neck Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mechanical Neck Pain
Keywords: Mechanical neck pain
Lead sponsor: Zonguldak Bulent Ecevit University
Sponsor class: OTHER
First posted: 2025-03-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study was to investigate the effects of oculomotor training on pain, cervical range of motion, joint position sense, endurance and balance in individuals with mechanical neck pain.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with mechanical neck pain
* Neck pain lasting longer than 3 weeks
* Individuals aged 18-50 years
* Score of 5 or higher on the Neck Disability Index

Exclusion Criteria:

* Having received physical therapy in the last 6 months
* Presence of congenital anomaly on cervical radiography
* Neurological deficit detected in physical examination
* Diagnosis of vertebrobasilar artery insufficiency
* Diagnosis of vestibular disease
* Presence of a rheumatic disease
* Presence of structural scoliosis
* History of spinal surgery
* Pregnancy
* Malignancy
* Eye disease/strabismus other than refractive errors
* Active use of anti-inflammatory medication
* Any mental condition that may prevent adherence to exercises

Primary outcomes:
measure: Visual Analog Scale
timeFrame: From enrollment to the end of treatment at 6 weeks
Secondary outcomes:
measure: Neck Disability Index
timeFrame: From enrollment to the end of treatment at 6 weeks
measure: Craniovertebral Angle
timeFrame: From enrollment to the end of treatment at 6 weeks
measure: Cervical ROM
timeFrame: From enrollment to the end of treatment at 6 weeks
measure: Craniocervical Flexion Test
timeFrame: From enrollment to the end of treatment at 6 weeks
measure: Y Balance Test
timeFrame: From enrollment to the end of treatment at 6 weeks
measure: Beck Depression Inventory
timeFrame: From enrollment to the end of treatment at 6 weeks
Other outcomes:
Locations:
city: Zonguldak
country: Turkey
facility: Zonguldak Bülent Ecevit University
Study officials:
References:
Clinical trial NCT05410665: The Roles of IL-9/E-cadherin and Ferroptosis in Intestinal Mucosal Barrier Injury in Sepsis
Official title: The Roles of IL-9/E-cadherin and Ferroptosis in Intestinal Mucosal Barrier Injury in Sepsis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Intestinal Mucosal Barrier
Ferroptosis
Lead sponsor: Nanjing First Hospital, Nanjing Medical University
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Septic patients and baseline data (including age, sex, body-mass index, disease severity scores) matched adult non-septic critical patients in ICU.

Brief summary: The investigators aim to evaluate the roles of IL-9/E-cadheirin and ferroptosis in the intestinal mucosal barrier injury of sepsis. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of sepsis
2. Within 3 days of sepsis onset before ICU admission
3. No artificial nutrition (enteral or parenteral nutrition) were provided before ICU admission

Exclusion Criteria:

1. Ileus
2. Digestive tract hemorrhage
3. Inflammatory bowel disease
4. Cancer or chronic organ dysfunction (e.g., hepatic or renal dysfunction)
5. Malnutrition or immunodeficiency
6. Long-term use of hormones

Primary outcomes:
measure: Incidence of intestinal barrier injury incidence of intestinal barrier injury
timeFrame: 7 days
Secondary outcomes:
measure: Incidence of ferroptosis
timeFrame: 7 days
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing First Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing First Hospital, Nanjing Medical University
name: Jia-Kui Sun, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00517465: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
Official title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus Type 2
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2007-08-17
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This 4 arm study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of R1511 compared to placebo in patients with type 2 diabetes mellitus. The starting dose of R1511 will be 100mg po bid for 5 1/2 days; this dose will be escalated in subsequent groups of patients to a potential maximum of 1200mg po bid for 5 1/2 days after a satisfactory assessment of blinded safety, tolerability, pharmacokinetic and pharmacodynamic data of the previous dose. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients, 18-65 years of age;
* type 2 diabetic patients;
* naive to anti-diabetic therapy, or taken off current anti-diabetic therapy for \>=2 weeks before first treatment.

Exclusion Criteria:

* type 1 diabetes mellitus;
* clinically significant cardiovascular disease.

Primary outcomes:
measure: AEs, laboratory parameters, vital signs.
timeFrame: Throughout study
measure: Glucose AUC
timeFrame: Days -1, 1 and 8.
Secondary outcomes:
measure: Insulin, C-peptide, glucagon and GLP-1 AUC
timeFrame: Days -1, 1 and 8
measure: 24h glucose
timeFrame: Days -1, 1 and 8
measure: Lipid profiles
timeFrame: Days -1 and 8
measure: Pharmacokinetic parameters
timeFrame: Days 1 and 8
Other outcomes:
Locations:
city: Berlin
country: Germany
city: Neuss
country: Germany
city: Balatonfuered
country: Hungary
city: Budapest
country: Hungary
city: Bratislava
country: Slovakia
city: Bratislava
country: Slovakia
city: Slough
country: United Kingdom
city: Welwyn Garden City
country: United Kingdom
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00954265: Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)
Official title: Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Embryonic Development
Pregnancy
VEGF
Keywords: pregnancy occurence
OHSS
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Merck Serono International SA
First posted: 2009-08-07
Enrollment: 130
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment


Eligibility criteria: Inclusion Criteria:

* FSH\<12,
* normal sperm,less than 36y,
* single blastocyst transfer

Exclusion Criteria:

* endometriosis stage 3\&4,
* pco

Primary outcomes:
measure: blastulation rate
timeFrame: on day-5
Secondary outcomes:
measure: pregnancy rates, VEGF levels, OHSS rate
timeFrame: 14 days after oocyte pick up
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Centre for Reproductive Medicine, UZ Brussel
state: Jette
Study officials:
affiliation: Professor or OB-GYN
name: Paul Devroey, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02041065: Waterjet Versus Ultrasound Dissection During Hepatic Transection
Official title: Waterjet Versus Ultrasound Dissection During Hepatic Transection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Liver Tumour
Keywords: Liver transection
Bloodloss
Operation time
Safety
feasibility
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Bengt Isaksson
name: Jansson, Anders, M.D.
First posted: 2014-01-20
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Before liver transection patients are allocated to either waterjet or CUSA to divide the liver parenchyma.

Detailed description: Transection time, bloodloss, total operation time and postoperative complication rates are registered.

Eligibility criteria: Inclusion Criteria:

* Hepatic tumour suitable for resection
* patients 18 year or older Segmental resection Local resection Left sided hemihepatectomy

Exclusion Criteria:

* Right sided hemihepatectoyReresection In Situ Split Liver Extended left- and rightsided hemihepatectomy Lobus caudatus resection Central resections Hilus tumour/Klatskin/Cholangiocarcinoma Surgery on biliary tree Extended resection on other organs

Resection on gallbladder Resection on other organs during the same operation.

Primary outcomes:
measure: Peroperative bloodloss
timeFrame: During liver transection (on an average<90 min)
Secondary outcomes:
measure: Transection time in minutes
timeFrame: During liver transection (on an average< 90 minutes)
measure: Operation time in minutes
timeFrame: Time spent in theater in minutes (on an average <240 minutes)
measure: Hospital stay in days
timeFrame: Days spent in hospital after surgery (on an average < 10 days)
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital, Centra of Gastroenterology
Study officials:
affiliation: Karolinska University Hospital
name: Anders Jansson, MdPhd
role: STUDY_CHAIR
affiliation: Karolinska University Hospital
name: Lars Lundell, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02523365: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma
Official title: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cervical Carcinoma
Keywords: Cervical Carcinoma
HepaSphere
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-08-14
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma.

Detailed description: By enrolling patients with cervical carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma.

Eligibility criteria: Inclusion Criteria:

1. Age:18-80
2. Karnofsky performance status \>60
3. Diagnosis of cervical carcinoma based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Will receive interventional therapy
6. Life expectancy: Greater than 3 months
7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities
8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other primary tumor except cervical carcinoma
2. History of coagulation disorders or anemia

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 1 year
Secondary outcomes:
measure: Percentage of lesions interventional therapy that show no sign of recurrence 12 months after
timeFrame: 1 year
measure: Progress free disease (PFS)
timeFrame: 1 year
measure: Overall survival (OS)
timeFrame: 3 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Central laboratory in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
citation: Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.
Clinical trial NCT05488665: The COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique
Official title: The COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2022-08-04
Enrollment: 512
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this COMPLETE randomized trial, using the contemporary second-generation drug-eluting stent, we aimed to test whether the crush technique is superior to the culotte technique for the treatment of bifurcation lesions in terms of 1-year target-lesion failure.


Eligibility criteria: Inclusion criteria:

1. Age ≥19 years
2. De novo coronary lesions eligible for drug-eluting stent implantation
3. Medina 1,1,1 or 1,0,1 or 0,1,1 de novo bifurcation lesions (LM or non-LM) and those of main vessel or side branch can be covered by 2 stents
4. Reference vessel diameter of side branch ≥2.5 mm by visual estimation

Exclusion criteria

1. Current or potential pregnancy
2. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
3. Subjects with ST elevation myocardial infarction \<24 h from the onset of chest pain
4. Cardiogenic Shock

Primary outcomes:
measure: Target lesion failure
timeFrame: 1 year
Secondary outcomes:
measure: Cardiovascular death
timeFrame: 1 year
measure: Target vessel myocardial infarction
timeFrame: 1 year
measure: Clinically driven target-lesion revascularization
timeFrame: 1 year
measure: All-cause of death
timeFrame: 1 year
measure: Target-vessel or non-target vessel myocardial infarction
timeFrame: 1 year
measure: Definite or probable stent thrombosis
timeFrame: 1 year
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System, Severance Hospital
Study officials:
affiliation: Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
name: Byeong-Keuk Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03235765: Cancer Panel From Blood of Lung Cancer Patients
Official title: Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer Recurrent
Keywords: NSCLC
Cancer panel
NGS
Actionable mutation
Immune checkpoint inhibitor
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: MACROGEN
First posted: 2017-08-01
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inoperable non-small cell lung cancer with two cohorts as below:

1. Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
2. Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.

Brief summary: Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).

Detailed description: This study is comprised of two cohorts as below:

Cohort A: inoperable, untreated, non-small cell lung cancer patients

Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors

Eligibility criteria: Inclusion Criteria:

* Provision of informed consent prior to any study specific procedures, sampling, and analyses
* Pathologically confirmed non-small cell lung cancer
* Male or female, aged at least 20 years
* Matches one of two criteria :

  1. Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
  2. Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.

Exclusion Criteria:

* Any concurrent and/or other active malignancy that has required treatment within 3 years
* Patients with mixed small cell histology
* Life expectancy less than 3 months
* Insufficient tissue for NGS test

Primary outcomes:
measure: Concordance rate
timeFrame: an average of one year
Secondary outcomes:
measure: Overall survival
timeFrame: an average of one year
measure: Frequency of actionable genomic change
timeFrame: an average of one year
measure: Overall survival by treatment
timeFrame: an average of one year
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
References: